Who is sponsoring NCT05547074?

NCT05547074 is sponsored by Zhejiang University.

What drugs are being tested in NCT05547074?

Interventions in NCT05547074: pancreatic cancer surgery.

What condition does NCT05547074 study?

NCT05547074 studies Neoplasms Pancreatic.

Is NCT05547074 still recruiting?

NCT05547074 is currently completed. Last updated 22 September 2022.

Last reviewed 2022-09-22 · How we verify

NCT05547074

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A New Prognostic Score Model for Pancreatic Ductal Adenocarcinoma

Completed Last updated 22 September 2022

What this trial tests

trial testing pancreatic cancer surgery in Neoplasms Pancreatic in 302 participants. Completed in 31 August 2022.

Timeline

1 September 2019

Primary endpoint
30 October 2020

31 August 2022

Quick facts

Lead sponsor	Zhejiang University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	302
Start date	1 September 2019
Primary completion	30 October 2020
Estimated completion	31 August 2022
Sites	1 location across China

Drugs / interventions tested

pancreatic cancer surgery

Conditions studied

Neoplasms Pancreatic — all drugs for Neoplasms Pancreatic →

Sponsor

Zhejiang University

Who can join

Eligibility, any sex, with Neoplasms Pancreatic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The AJCC TNM staging system is the prevailing method in prognostic evaluation of pancreatic ductal adenocarcinoma (PDAC) at present , but it did not include factors such as the tumor immune microenvironment that are known to exert a profound impact on patients'clinical outcome. This study was aimed to develop a comprehensive and effective prognostic score model to predict prognosis and guide clinical management for postoperative PDAC patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Neoplasms Pancreatic

Currently open trials in the same condition.

NCT05669482 — Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer · Phase 1, PHASE2 · active not recruiting

Other Zhejiang University trials

Trials by the same sponsor.

NCT07487402 — Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurr · EARLY_PHASE1 · not yet recruiting
NCT07480044 — A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly · NA · not yet recruiting
NCT07467005 — Video Double-Lumen Tube for Secondary Pulmonary Resection · NA · not yet recruiting
NCT07429461 — Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
NCT07240766 — HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05547074 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhejiang University
Last refreshed: 22 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05547074.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing